The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Real-world racial disparities in treating EGFR-m NSCLC with osimertinib
Matthew Lee, MD, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, discusses findings from a real-world, retrospective study analyzing the impact of race, adherence, and socioeconomic factors on clinical outcomes in patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated with osimertinib. The study revealed no significant differences in adherence between racial/ethnic groups, but non-Hispanic Black patients exhibited worse overall survival (OS) compared to non-Hispanic Whites, despite similar treatment adherence. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
